Filing Details

Accession Number:
0001140361-15-001940
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-01-15 17:22:05
Reporting Period:
2015-01-14
Filing Date:
2015-01-15
Accepted Time:
2015-01-15 17:22:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184149 W Jonathan Ayers One Idexx Drive
Westbrook ME 04092
Chairman, President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-01-14 28,512 $28.66 459,642 No 4 M Direct
Common Stock Disposition 2015-01-14 100 $153.70 459,542 No 4 S Direct
Common Stock Disposition 2015-01-14 4,200 $155.52 455,342 No 4 S Direct
Common Stock Disposition 2015-01-14 3,300 $156.03 452,042 No 4 S Direct
Common Stock Disposition 2015-01-14 1,593 $157.23 450,449 No 4 S Direct
Common Stock Disposition 2015-01-14 15,824 $158.38 434,625 No 4 S Direct
Common Stock Disposition 2015-01-14 3,495 $158.99 431,130 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2015-01-14 28,512 $0.00 28,512 $28.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-02-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 49,000 Indirect By Ayers Family Trust
Footnotes
  1. Includes 49 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 12/31/2014.
  2. The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2014.
  3. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $154.765 to $155.75, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5, 6 and 7 to this Form 4.
  4. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $155.76 to $156.41, inclusive.
  5. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $156.855 to $157.72, inclusive.
  6. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $157.90 to $158.86, inclusive.
  7. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $158.91 to $159.00, inclusive.
  8. Grant of options to buy shares of common stock that became exercisable as to 20,000 shares on 02/03/2006, 02/03/2007, 02/03/2008 and 02/03/2009, and the remaining 16,512 shares on 02/03/2010.